SCHEMBL2403531

SCHEMBL2403531

Cc1cccc(-c2nccnc2C(=O)O)c1C

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NUDT1 P36639 3/20 0.43
MYC P01106 2/20 0.40
CTSA P10619 1/20 0.40
KDM4E B2RXH2 6/20 0.40
ALDH1A1 P00352 4/20 0.40
CYP3A4 P08684 2/20 0.40
MAPT P10636 1/20 0.40
ALOX15 P16050 1/20 0.40
TSHR P16473 1/20 0.40
BLM P54132 1/20 0.40
AGER Q15109 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
ATM Q13315 1/20 0.39
PDE10A Q9Y233 1/20 0.37
NPC1 O15118 1/20 0.37
RAB9A P51151 1/20 0.37
TDP1 Q9NUW8 2/20 0.37
KMT2A Q03164 2/20 0.36
MEN1 O00255 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3398695 0.87 KDM4E (0.44) MYCKDM4EALDH1A1CYP3A4MAPT
SCHEMBL3387693 0.76 KDM4E (0.46) NUDT1MYCKDM4EALDH1A1CYP3A4
SCHEMBL10000615 0.75 MYC (0.38) MYCKDM4EALDH1A1CYP3A4MAPT
SCHEMBL11811785 0.74 NUDT1 (0.49) NUDT1MYCCTSAKDM4EALDH1A1
SCHEMBL22883855 0.73 CYP2A6 (0.48) NUDT1KDM4EMAPTBLML3MBTL1
SCHEMBL31265696 0.71 KDM4E (0.52) MYCKDM4EALDH1A1CYP3A4MAPT
SCHEMBL698990 0.71 KDM4E (0.52) MYCKDM4EALDH1A1CYP3A4MAPT
SCHEMBL7199668 0.71 KDM4E (0.47) MYCKDM4EALDH1A1CYP3A4MAPT
SCHEMBL130171 0.71 KDM4E (0.61) MYCKDM4EALDH1A1CYP3A4MAPT
SCHEMBL29564333 0.71 KDM4E (0.61) MYCKDM4EALDH1A1CYP3A4MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102164896-A Phenethylamide derivatives and their heterocyclic analogues ACTELION PHARMACEUTICALS LTD 2011-08-24 CN claimed
WO-2010044054-A1 PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES ACTELION PHARMACEUTICALS LTD (CH) 2010-04-22 WO claimed
US-20110212968-A1 PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES ACTELION PHARMACEUTICALS LTD. (CH) 2011-09-01 US disclosed
CN-102164896-A Phenethylamide derivatives and their heterocyclic analogues ACTELION PHARMACEUTICALS LTD 2011-08-24 CN disclosed
WO-2010044054-A1 PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES ACTELION PHARMACEUTICALS LTD (CH) 2010-04-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110212968-A1 PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES HCRTR2, HCRTR1, HRH3 NUDT1 2771/4885MYC 3302/4885CTSA 731/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.